# A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

> **NCT00854802** · NA · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 290 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Debio 025
- **DRUG:** Peg-IFNα2a
- **DRUG:** Ribavirin
- **DRUG:** Debio 025 placebo

## Key facts

- **NCT ID:** NCT00854802
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2016-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854802, "A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00854802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*